Company: SCLXW
Filing Date: 2025-08-04
Form Type: S-1
Source: 0001193125-25-172703
Chunk: 594

Company: Scilex Holding Co
Filing Date: 2025-08-04
Form: S-1
Chunk 594
---
 of each of March 31, 2025 and December 31, 2024, there were 15,000,000April 2024 RDO Common Warrants, which are currently exercisable for an aggregate of up to 428,572shares of Common Stock outstanding and 1,200,000April 2024 RDO Placement Agent Warrants, which are currently exercisable for an aggregate of up to 34,286shares of our Common Stock outstanding. December 2024 Registered Direct Offering On December 11, 2024, the Company entered into a securities purchase agreement (the “December 2024 RDO Purchase Agreement”) with the investors named therein, pursuant to which the Company agreed to sell and issue, in a registered direct offering (the “December 2024 RDO”): (i) an aggregate of 753,009shares of Common Stock, (ii) pre-fundedwarrants to purchase up to 68,604shares of Common Stock (the “December 2024 RDO Pre-FundedWarrants”) and (iii) common warrants to purchase up to 1,642,871shares of Common Stock (the “December 2024 RDO Common Warrants” and collectively with the December 2024 RDO Pre-FundedWarrants and the warrants issued to StockBlock pursuant to certain contractual obligations between the Company and StockBlock (the “StockBlock Warrants”), the “December 2024 RDO Warrants”). The combined offering price (a) per share of Common Stock and accompanying December 2024 RDO Common Warrants was $ 20.65and (b) per December 2024 RDO Pre-FundedWarrant and accompanying December 2024 RDO Common Warrants was $ 20.6499. The aggregate gross proceeds to the Company from the December 2024 RDO were approximately $ 17.0million, before deducting offering fees and expenses. The Company intends to use the net proceeds from the December 2024 RDO for working capital and general corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. The Company accounted for the December 2024 RDO Common Warrants and December 2024 RDO Pre-FundedWarrants as liability classified instruments (see Note 4) and the StockBlock Warrants